Wainwright raises Nektar's price target to $120 after positive Phase 2b study results

From Yahoo Finance: 2025-06-25 12:20:00

H.C. Wainwright analyst Arthur He raises Nektar’s price target to $120 and maintains a Buy rating. Positive results from Phase 2b study show potential for atopic dermatitis drug to reshape treatment landscape. Stock jumps 134% to $22.36. Next clinical update expected in Q1 2026.

Source: TheFly

For more information on Nektar, visit TipRanks for Disclaimer & Disclosure and to Report an Issue.

Read more: Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data